Surgical Research Projects

Share on Facebook Share on X Share on LinkedIn Email

Faculty/Staff Projects

  • Tao Gao, PhD:
    • Epigenetic therapy for pancreatic neuroendocrine tumor (PNET)
  • Weam Elbezanti, PharmB, MS, PhD:
    • Epigenetic treatments and their effects on tumor microenvironment
    • HIPEC with epigenetic drugs for peritoneal carcinomatosis of colorectal cancer
    • The effect of histotripsy on immune activation and cancer eradication
  • Hyun-Kyung Ko, PhD:
    • Targeting c-Myc and IGFBP2 for gastric cancer therapy
  • Oscar Pellon, PhD:
    • Mechanism and therapy of sarcoma
    • Chemoresistance in Ovarian Cancer and The Role of NRF2
  • Boopathi Subramaniyan, M.Phil, PhD:
    • NRF2-responsive kinases in esophageal squamous cell carcinoma
  • Huan Li, PhD:
    • Chemo- and radio-sensitization of cancer cells
  • Yahui Li, MS:
    • Lymphatic metastasis of esophageal squamous cell carcinoma
  • Xiaoxin Luke Chen, MD, PhD:
    • NRF2 in esophageal squamous cell carcinoma and alcohol-associated esophageal pathology
  • Madeline Torres, MD:
    • Mechanism and therapy of sarcoma
    • Targeting c-Myc and IGFBP2 for gastric cancer therapy
  • Young Ki Hong, MD:
    • Epigenetic therapy for pancreatic neuroendocrine tumor (PNET)
    • HIPEC with epigenetic drugs for peritoneal carcinomatosis of colorectal cancer
  • Francis Spitz, MD:
    • Target NRF2 for cancer therapy
Trainee Projects
  • Ryan Field: The YAP1-IGFBP2 axis as a predictive biomarker and therapeutic target in gastric cancer metastasis
  • Elizabeth Hilt: Targeting increased YAP/TAZ activity in Liposarcoma
  • Jonathan Kolansky: AI-assisted design of NRF2 inhibitors for cancer therapy
  • Aara Sheth: Development of Novel Preclinical Murine Models for Epigenetic–Immunotherapy in Pancreatic Neuroendocrine Tumors
  • Nida Hasan: Chemoresistance in Ovarian Cancer and The Role of NRF2
  • Michael C. Wang, MD: AI-assisted Development of Small Molecule Degraders of NRF2Mut Protein for Cancer Therapy
  • Ami Kalola, MD: Development of a murine model to investigate epigenetic and immunomodulatory treatments in pancreatic neuroendocrine tumors
  • Emma Dragan, MD: Targeting activated kinases (SRC/MET) in CDH1-deficient diffuse gastric cancer
  • Emily Hancin, MD: Targeting activated kinases (SRC/MET) in CDH1-deficient diffuse gastric cancer
  • Hannah Hong, DO: Mechanistic Insights and Therapeutic Approaches to Peritoneal Metastasis of Ovarian Cancer
  • Zachary Ladd, MS: Development of NRF2Mut inhibitors for NRF2Mut esophageal cancer
  • T. Hess, MD: Identifying the role of NRF2 in non-small cell lung cancer differentiation and treatment
  • Rachel Nation, MD: Development of a murine model to investigate epigenetic and immunomodulatory treatments in pancreatic neuroendocrine tumors
  • Hannah Sofield, MD: Targeting activated kinases (SRC/MET) in CDH1-deficient diffuse gastric cancer
  • Gena Topper, MD: Intraperitoneal epigenetic drug perfusion for colorectal cancer-associated peritoneal carcinomatosis
  • Chelsea Katz, MD: The resistance to chemotherapy in high-grade serous ovarian cancer and the role of NRF2
  • Zachary Ladd, MS: Development of NRF2Mut inhibitors for NRF2Mut esophageal cancer
  • Matthew Moccia, MD: Epigenetic therapy for pancreatic neuroendocrine tumor (PNET)
  • Hansa Joshi, MD: Identification of Molecular Pathways Associated with Non-Small Cell Lung Cancer Subtype Switching after Treatment
  • Yazid Khalil Mo Ghanem, MD: Intraperitoneal epigenetic drug perfusion for colon cancer-associated peritoneal carcinomatosis
  • Helen Toma, MD: Chemotherapy Resistance in Ovarian Cancer and the Role of NRF2
  • Zena Saleh, MD: Epigenetic alterations are associated with gene silencing and immune infiltration in human PNET
  • Zachary Ladd, BS: Development of novel NRF2 inhibitors